Trevor Hawkins

3.3k total citations
29 papers, 1.5k citations indexed

About

Trevor Hawkins is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Trevor Hawkins has authored 29 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Infectious Diseases, 15 papers in Virology and 10 papers in Epidemiology. Recurrent topics in Trevor Hawkins's work include HIV/AIDS drug development and treatment (16 papers), HIV Research and Treatment (15 papers) and HIV/AIDS Research and Interventions (9 papers). Trevor Hawkins is often cited by papers focused on HIV/AIDS drug development and treatment (16 papers), HIV Research and Treatment (15 papers) and HIV/AIDS Research and Interventions (9 papers). Trevor Hawkins collaborates with scholars based in United States, United Kingdom and France. Trevor Hawkins's co-authors include Brian P. Kearney, Edwin DeJesus, Robert L. St. Claire, Bill Guyer, Calvin Cohen, Richard Elion, Martin Markowitz, Daniel Berger, Peter Ruane and Andrew Cheng and has published in prestigious journals such as Gastroenterology, Neurology and Clinical Infectious Diseases.

In The Last Decade

Trevor Hawkins

28 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Trevor Hawkins United States 17 992 726 368 223 191 29 1.5k
Susan L. Ford United States 22 1.5k 1.5× 1.1k 1.5× 391 1.1× 215 1.0× 166 0.9× 56 1.8k
Brian Woodfall United States 20 1.8k 1.8× 1.4k 1.9× 363 1.0× 208 0.9× 186 1.0× 29 1.9k
Keith A. Pappa United States 16 1.3k 1.3× 986 1.4× 215 0.6× 394 1.8× 129 0.7× 36 1.5k
Laura Else United Kingdom 25 1.2k 1.3× 711 1.0× 353 1.0× 200 0.9× 114 0.6× 84 1.6k
Uriel Sandkovsky United States 17 897 0.9× 623 0.9× 403 1.1× 206 0.9× 149 0.8× 48 1.5k
Sulaimon Akanmu Nigeria 22 825 0.8× 452 0.6× 491 1.3× 104 0.5× 107 0.6× 139 1.7k
Brian L. Robbins United States 21 1.1k 1.1× 654 0.9× 397 1.1× 154 0.7× 295 1.5× 43 1.4k
Amedeo Capetti Italy 21 956 1.0× 719 1.0× 319 0.9× 291 1.3× 243 1.3× 74 1.5k
Takuma Shirasaka Japan 21 696 0.7× 539 0.7× 337 0.9× 116 0.5× 210 1.1× 87 1.4k
Paul A. Pham United States 17 1000 1.0× 507 0.7× 457 1.2× 375 1.7× 99 0.5× 38 1.5k

Countries citing papers authored by Trevor Hawkins

Since Specialization
Citations

This map shows the geographic impact of Trevor Hawkins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Trevor Hawkins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Trevor Hawkins more than expected).

Fields of papers citing papers by Trevor Hawkins

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Trevor Hawkins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Trevor Hawkins. The network helps show where Trevor Hawkins may publish in the future.

Co-authorship network of co-authors of Trevor Hawkins

This figure shows the co-authorship network connecting the top 25 collaborators of Trevor Hawkins. A scholar is included among the top collaborators of Trevor Hawkins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Trevor Hawkins. Trevor Hawkins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Liu, Ying, Jacquelyn Bainbridge, Stefan Sillau, et al.. (2024). Short‐Term Cannabidiol with Δ‐9‐Tetrahydrocannabinol in Parkinson's Disease: A Randomized Trial. Movement Disorders. 39(5). 863–875. 10 indexed citations
2.
Pons‐Faudoa, Fernanda P., Nicola Di Trani, Antons Sizovs, et al.. (2020). Viral load Reduction in SHIV-Positive Nonhuman Primates via Long-Acting Subcutaneous Tenofovir Alafenamide Fumarate Release from a Nanofluidic Implant. Pharmaceutics. 12(10). 981–981. 99 indexed citations
3.
Hawkins, Trevor & Brian D. Berman. (2017). Pimavanserin. Neurology Clinical Practice. 7(2). 157–162. 28 indexed citations
4.
5.
6.
Berkowitz, Elchonon M., Graeme Moyle, Hans‐Jürgen Stellbrink, et al.. (2014). Safety and Immunogenicity of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in HIV-Infected Adults: A Phase 1/2a Randomized, Placebo-Controlled Study. The Journal of Infectious Diseases. 211(8). 1279–1287. 144 indexed citations
7.
MacArthur, Rodger D., Trevor Hawkins, Stephen J. Brown, et al.. (2013). Efficacy and Safety of Crofelemer for Noninfectious Diarrhea in HIV-Seropositive Individuals (ADVENT Trial): A Randomized, Double-Blind, Placebo-Controlled, Two-Stage Study. HIV Clinical Trials. 14(6). 261–273. 29 indexed citations
8.
Elion, Richard, Calvin Cohen, Joseph Gathe, et al.. (2011). Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection. AIDS. 25(15). 1881–1886. 76 indexed citations
9.
Min, Sherene, Louis Sloan, Edwin DeJesus, et al.. (2011). Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS. 25(14). 1737–1745. 171 indexed citations
10.
Hawkins, Trevor, et al.. (2011). Intracellular Nucleotide Levels during Coadministration of Tenofovir Disoproxil Fumarate and Didanosine in HIV-1-Infected Patients. Antimicrobial Agents and Chemotherapy. 55(4). 1549–1555. 15 indexed citations
11.
Young, Benjamin, Edwin DeJesus, Trevor Hawkins, et al.. (2010). A Pilot Study of Abacavir/Lamivudine and Raltegravir in Antiretroviral-Naïve HIV-1–Infected Patients: 48-Week Results of the SHIELD Trial. HIV Clinical Trials. 11(5). 260–269. 17 indexed citations
12.
Hawkins, Trevor. (2009). Understanding and managing the adverse effects of antiretroviral therapy. Antiviral Research. 85(1). 201–209. 129 indexed citations
13.
Winston, Jonathan, Gilbert Deray, Trevor Hawkins, et al.. (2008). Kidney Disease in Patients with HIV Infection and AIDS. Clinical Infectious Diseases. 47(11). 1449–1457. 82 indexed citations
14.
Elion, Richard, et al.. (2007). Advances in HIV therapeutics: news from the 4th International AIDS Society Conference.. PubMed. 17(10). 484–90. 2 indexed citations
15.
Hawkins, Trevor. (2006). Appearance-Related Side Effects of HIV-1 Treatment. AIDS Patient Care and STDs. 20(1). 6–18. 46 indexed citations
16.
DeJesus, Edwin, Daniel Berger, Martin Markowitz, et al.. (2006). Antiviral Activity, Pharmacokinetics, and Dose Response of the HIV-1 Integrase Inhibitor GS-9137 (JTK-303) in Treatment-Naive and Treatment-Experienced Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes. 43(1). 1–5. 223 indexed citations
17.
Hawkins, Trevor. (2006). HIV drug resistance and you. The limitations of drug resistance testing. Many factors influence the results.. PubMed. Spec No. 13–6. 3 indexed citations
18.
Hawkins, Trevor, et al.. (2005). Intracellular Pharmacokinetics of Tenofovir Diphosphate, Carbovir Triphosphate, and Lamivudine Triphosphate in Patients Receiving Triple-Nucleoside Regimens. JAIDS Journal of Acquired Immune Deficiency Syndromes. 39(4). 406–411. 172 indexed citations
19.
Hawkins, Trevor. (2004). Impact of once- and twice-daily dosing regimens on adherence and overall safety.. PubMed. 14(6). 320–2, 324, 329. 17 indexed citations
20.
Hawkins, Trevor, et al.. (1988). AIDS: knowledge and attitudes in Otago.. PubMed. 101(845). 241–3. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Susan L. Ford Breakdown of academic impact, for papers by Brian Woodfall Breakdown of academic impact, for papers by Keith A. Pappa Breakdown of academic impact, for papers by Laura Else Breakdown of academic impact, for papers by Uriel Sandkovsky Breakdown of academic impact, for papers by Sulaimon Akanmu Breakdown of academic impact, for papers by Brian L. Robbins Breakdown of academic impact, for papers by Amedeo Capetti Breakdown of academic impact, for papers by Takuma Shirasaka Breakdown of academic impact, for papers by Paul A. Pham
Rankless by CCL
2026